Cardiovascular Research Advance Access originally published online on December 4, 2007
Cardiovascular Research 2008 77(4):659-666; doi:10.1093/cvr/cvm084
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sarcomeric proteins and inherited cardiomyopathies
Laboratory of Clinical Pharmacology, Kyushu University Graduate School of Medicine, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan
* Corresponding author. Tel: +81 92 642 6081; fax: +81 92 642 6084. E-mail address: morimoto{at}med.kyushu-u.ac.jp
Over the last two decades, a large number of mutations have been identified in sarcomeric proteins as a cause of hypertrophic, dilated or restrictive cardiomyopathy. Functional analyses of mutant proteins in vitro have revealed several important functional changes in sarcomeric proteins that might be primarily involved in the pathogenesis of each cardiomyopathy. Creation of transgenic or knock-in animals expressing mutant proteins in their hearts confirmed that these mutations in genes for sarcomeric proteins induced distinct types of cardiomyopathies and provided useful animal models to explore the molecular pathogenic mechanisms and potential therapeutics of cardiomyopathy in vivo. In this review, I discuss the functional consequences of mutations in different sarcomeric proteins found in hypertrophic, dilated, and restrictive cardiomyopathies in conjunction with their effects on cardiac structure and function in vivo and their possible molecular and cellular mechanisms, which underlie the pathogenesis of these inherited cardiomyopathies.
KEYWORDS Sarcomere; Gene mutation; Hypertrophic cardiomyopathy; Dilated cardiomyopathy; Restricted cardiomyopathy
Time for primary review: 17 days
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
D.-Y. Zhan, S. Morimoto, C.-K. Du, Y.-Y. Wang, Q.-W. Lu, A. Tanaka, T. Ide, Y. Miwa, F. Takahashi-Yanaga, and T. Sasaguri Therapeutic effect of {beta}-adrenoceptor blockers using a mouse model of dilated cardiomyopathy with a troponin mutation Cardiovasc Res, June 17, 2009; (2009) cvp168v2. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Z. Armel and L. A. Leinwand Mutations in the {beta}-myosin rod cause myosin storage myopathy via multiple mechanisms PNAS, April 14, 2009; 106(15): 6291 - 6296. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. S. Willis, J. C. Schisler, A. L. Portbury, and C. Patterson Build it up-Tear it down: protein quality control in the cardiac sarcomere Cardiovasc Res, February 15, 2009; 81(3): 439 - 448. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Solaro and P. P. de Tombe Review focus series: sarcomeric proteins as key elements in integrated control of cardiac function Cardiovasc Res, March 1, 2008; 77(4): 616 - 618. [Full Text] [PDF] |
||||

